PMV Pharmaceuticals, Inc. (PMVP) shareholders
Close on Nov 17, 2026Market cap $65.22MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Srinivas Akkaraju Joint filing with Samsara BioCapital, L.P. (5.00%), Samsara BioCapital GP, LLC (5.00%) and 2 more | 7,577,467 | 9.90% | 13G (passive) | Sep 2, 2026 |
| BML Investment Partners, L.P. | 5,292,000 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp V LLC (9.40%) | 4,975,291 | 9.40% | 13D (active) amendment | Oct 23, 2025 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (8.90%), Tang Capital Partners, LP (5.00%) | 4,720,357 | 8.90% | 13G (passive) | Sep 16, 2025 |
| Partner Asset Management, LLC Joint filing with PFM Health Sciences, LP (6.40%), PFM Health Sciences GP, LLC (6.40%) and 1 more | 3,301,942 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PMVP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 5,330,000 | 9.97% | $7.14M | +10,000 | 4.06% |
| Tang Capital Management LLC | 4,245,085 | 7.94% | $5.69M | – | 0.26% |
| Sio Capital Management, LLC | 2,634,137 | 4.93% | $3.53M | −442,443 | 0.58% |
| Euclidean Capital LLC | 2,627,643 | 4.92% | $3.52M | – | 0.80% |
| Adage Capital Partners Gp, L.L.C. | 2,360,000 | 4.41% | $3.16M | +500,000 | 0.00% |
| Acadian Asset Management LLC | 2,215,894 | 4.15% | $2.97M | – | 0.00% |
| Vanguard Capital Management LLC | 2,012,020 | 3.76% | $2.70M | +37,114 | 0.00% |
| ArrowMark Colorado Holdings LLC | 1,959,579 | 3.67% | $2.63M | −913,185 | 0.11% |
| Two Sigma Investments, LP | 1,954,136 | 3.66% | $2.62M | +69,606 | 0.00% |
| Eversept Partners, LP | 1,890,904 | 3.54% | $2.53M | −457,456 | 0.13% |
| BlackRock, Inc. | 919,818 | 1.72% | $1.23M | +45,444 | 0.00% |
| Assenagon Asset Management S.A. | 660,006 | 1.23% | $884.41K | +299,220 | 0.00% |
| Stonepine Capital Management, LLC | 536,086 | 1.00% | $718.36K | −172,016 | 0.41% |
| Geode Capital Management, LLC | 473,158 | 0.89% | $634.62K | −22,764 | 0.00% |
| Aldebaran Capital, LLC | 467,432 | 0.87% | $626.36K | −5,930 | 0.47% |
| Bridgeway Capital Management, LLC | 428,853 | 0.80% | $574.66K | – | 0.01% |
| BIT Capital GmbH | 407,555 | 0.76% | $546.12K | +284,000 | 0.02% |
| Verdad Advisers, LP | 362,361 | 0.68% | $485.56K | +182,200 | 0.47% |
| Walleye Capital LLC | 335,694 | 0.63% | $449.83K | – | 0.00% |
| Marshall Wace, Llp | 321,610 | 0.60% | $430.96K | −112,483 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 64 | 35M | 64.7% | 4 / 15 | 21 / 9 | 2M | 4M |
| Q1 2026 | 69 | 37M | 69.1% | 15 / 16 | 22 / 8 | 11M | 9M |
| Q4 2025 | 63 | 38M | 70.4% | 10 / 24 | 17 / 10 | 3M | 2M |
| Q3 2025 | 64 | 37M | 70.1% | 19 / 14 | 18 / 9 | 8M | 5M |
| Q2 2025 | 54 | 35M | 64.9% | 7 / 13 | 20 / 8 | 2M | 5M |
| Q1 2025 | 55 | 37M | 69.8% | 1 / 9 | 32 / 16 | 2M | 4M |
| Q4 2024 | 70 | 39M | 72.9% | 6 / 15 | 31 / 10 | 4M | 4M |
| Q3 2024 | 74 | 39M | 73.0% | 5 / 23 | 30 / 23 | 5M | 5M |
| Q2 2024 | 93 | 41M | 76.1% | 21 / 26 | 31 / 26 | 6M | 9M |
| Q1 2024 | 99 | 44M | 81.8% | 16 / 35 | 26 / 15 | 8M | 15M |
| Q4 2023 | 98 | 51M | 95.0% | 25 / 33 | 30 / 29 | 16M | 19M |
| Q3 2023 | 104 | 57M | 100.0% | 8 / 41 | 33 / 10 | 8M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
23 funds held PMVP in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PMVP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,487,065 | 2.78% | $1.99M | 0.00% | Jun 30, 2026 |
| Meridian Small Cap Growth Fund | 1,056,713 | 1.98% | $1.42M | 0.52% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 452,363 | 0.85% | $606.17K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 331,453 | 0.62% | $444.15K | 0.45% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 232,874 | 0.44% | $279.45K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 160,526 | 0.30% | $215.10K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 76,900 | 0.14% | $103.05K | 0.07% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 74,050 | 0.14% | $99.23K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 71,190 | 0.13% | $85.43K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 59,924 | 0.11% | $71.91K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 45,045 | 0.08% | $60.36K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 43,138 | 0.08% | $51.77K | 0.00% | May 31, 2026 |
| Tiff Multi-Asset Fund | 41,912 | 0.08% | $56.16K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 27,547 | 0.05% | $36.91K | 0.00% | Jun 30, 2026 |
| NVIT Small Cap Value Fund | 14,496 | 0.03% | $19.42K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Henry Mack | President and CEO, Director | 904,691 | 1.69% | Mar 9, 2026 |
| Robert Ticktin | General Counsel & COO | 98,695 | 0.18% | Mar 9, 2026 |
| Deepika Jalota | Chief Development Officer | 89,959 | 0.17% | Mar 9, 2026 |
| Michael Carulli | Chief Financial Officer | 73,848 | 0.14% | Mar 9, 2026 |
| Matthew Joseph Eckler | Director | – | – | Oct 5, 2026 |
| Laurie Stelzer | Director | – | – | Jun 5, 2026 |
| Carol Giltner Gallagher | Director | – | – | Jun 5, 2026 |
| Charles M. Baum | Director | – | – | Jun 5, 2026 |
| Arnold J. Levine | Director | 409,842 | 0.77% | Jun 5, 2026 |
| Kirsten Flowers | Director | – | – | Jun 5, 2026 |
| Richard A. Heyman | Director | 558 | 0.00% | Jun 9, 2025 |
| Capital GP V. LLC OrbiMed | 10% owner | 4,975,291 | 9.31% | Oct 27, 2025 |
| Advisors Llc Orbimed | 10% owner | 5,975,291 | 11.18% | Oct 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Henry Mack President and CEO, Director | Oct 27, 2025 | Option exercise | +220,643 | $1.37 | $302.28K | 451,109 |
| Capital GP V. LLC OrbiMed 10% owner | Oct 23, 2025 | Sale | −1,000,000 | $1.52 | $1.52M | 4,975,291 |
| Advisors Llc Orbimed 10% owner | Sep 10, 2025 | Sale | −500,000 | $1.80 | $900.00K | 5,975,291 |
| Robert Ticktin General Counsel & COO | Jul 1, 2025 | Sale | −23,151 | $1.06 | $24.54K | 98,695 |
| David Henry Mack President and CEO, Director | Jul 1, 2025 | Sale | −58,411 | $1.06 | $61.92K | 536,133 |
| Deepika Jalota Chief Development Officer | Jul 1, 2025 | Sale | −33,065 | $1.06 | $35.05K | 89,959 |
| Michael Carulli Chief Financial Officer | Jul 1, 2025 | Sale | −28,249 | $1.06 | $29.94K | 60,146 |
| David Henry Mack President and CEO, Director | Jan 3, 2025 | Option exercise | +17,709 | $0.53 | $9.39K | 551,919 |
| David Henry Mack President and CEO, Director | Dec 3, 2024 | Option exercise | +91,750 | $0.53 | $48.63K | 534,210 |
| Deepika Jalota Chief Development Officer | Sep 11, 2024 | Sale | −7,218 | $1.50 | $10.83K | 118,283 |
| Michael Carulli Chief Financial Officer | Sep 11, 2024 | Sale | −2,891 | $1.50 | $4.34K | 88,395 |
| Deepika Jalota Chief Development Officer | Jan 18, 2024 | Award | +95,555 | – | – | 125,501 |
| David Henry Mack President and CEO, Director | Jan 18, 2024 | Award | +163,890 | – | – | 442,460 |
| Michael Carulli Chief Financial Officer | Jan 18, 2024 | Award | +82,220 | – | – | 91,286 |
| Genesis GP LLC OrbiMed 10% owner | Nov 22, 2023 | Sale | −87,786 | $2.23 | $195.76K | 0 |
| David Henry Mack President and CEO, Director | Nov 10, 2023 | Gift | +85,307 | – | – | 165,307 |
| David Henry Mack President and CEO, Director | Nov 10, 2023 | Gift | −85,307 | – | – | 278,570 |
| David Henry Mack President and CEO, Director | Oct 18, 2023 | Option exercise | +198,407 | $0.53 | $105.16K | 363,877 |
| Deepika Jalota Chief Development Officer | Sep 15, 2023 | Sale | −4,104 | $6.62 | $27.17K | 29,946 |
| Leila Alland Chief Medical Officer | Sep 15, 2023 | Sale | −6,291 | $6.62 | $41.65K | 45,909 |
| David Henry Mack President and CEO, Director | Aug 7, 2023 | Option exercise | +85,500 | $0.53 | $45.32K | 165,470 |
| Winston Kung COO, CFO | Nov 25, 2022 | Gift | −2,560 | – | – | 10,600 |
| Deepika Jalota SVP, Regulatory Affairs and QA | Sep 9, 2022 | Award | +34,050 | – | – | 34,050 |
| Leila Alland Chief Medical Officer | Sep 9, 2022 | Award | +52,200 | – | – | 52,200 |
| Capital GP V. LLC OrbiMed 10% owner | May 26, 2022 | Sale | −26,253 | $15.93 | $418.21K | 87,786 |
| David Henry Mack President and CEO, Director | Apr 27, 2022 | Option exercise | +33,000 | $0.53 | $17.49K | 79,970 |
| Winston Kung COO, CFO | Apr 20, 2022 | Option exercise | +4,000 | $3.22 | $12.88K | 10,600 |
| Genesis GP LLC OrbiMed 10% owner | Mar 31, 2022 | Sale | −34,500 | $21.17 | $730.37K | 0 |
| Genesis GP LLC OrbiMed 10% owner | Mar 30, 2022 | Sale | −75,000 | $22.39 | $1.68M | 34,500 |
| Genesis GP LLC OrbiMed 10% owner | Mar 29, 2022 | Sale | −365,000 | $21.52 | $7.85M | 109,500 |
| David Henry Mack President and CEO, Director | Mar 8, 2022 | Option exercise | +20,000 | $1.37 | $27.40K | 46,970 |
| Winston Kung COO, CFO | Dec 30, 2021 | Gift | −2,725 | – | – | 6,600 |
| David Henry Mack President and CEO, Director | Dec 15, 2021 | Option exercise | +9,000 | $0.53 | $4.77K | 26,970 |
| David Henry Mack President and CEO, Director | Dec 9, 2021 | Gift | −40,000 | – | – | 187,915 |
| David Henry Mack President and CEO, Director | Dec 9, 2021 | Gift | +40,000 | – | – | 40,000 |
| Thilo Schroeder Director | Oct 6, 2021 | Sale(10b5-1 plan) | −800 | $30.15 | $24.12K | 1,101,283 |
| Thilo Schroeder Director | Oct 4, 2021 | Sale(10b5-1 plan) | −100 | $30.08 | $3.01K | 1,102,083 |
| Thilo Schroeder Director | Oct 1, 2021 | Sale(10b5-1 plan) | −11,541 | $30.10 | $347.38K | 1,102,183 |
| Thilo Schroeder Director | Sep 30, 2021 | Sale(10b5-1 plan) | −2,978 | $30.03 | $89.43K | 1,113,724 |
| Thilo Schroeder Director | Sep 29, 2021 | Sale(10b5-1 plan) | −5,708 | $30.04 | $171.47K | 1,116,702 |
| Thilo Schroeder Director | Sep 27, 2021 | Sale(10b5-1 plan) | −1,753 | $30.11 | $52.78K | 1,122,410 |
| Thilo Schroeder Director | Sep 22, 2021 | Sale(10b5-1 plan) | −100 | $30.00 | $3.00K | 1,124,163 |
| Arnold J. Levine Director | Sep 22, 2021 | Sale(10b5-1 plan) | −3,500 | $30.00 | $105.00K | 409,842 |
| Thilo Schroeder Director | Sep 17, 2021 | Sale(10b5-1 plan) | −711 | $30.03 | $21.35K | 1,124,263 |
| Thilo Schroeder Director | Sep 13, 2021 | Sale(10b5-1 plan) | −13,272 | $30.20 | $400.81K | 1,124,974 |
| Thilo Schroeder Director | Sep 10, 2021 | Sale(10b5-1 plan) | −38,056 | $30.44 | $1.16M | 1,143,417 |
| Thilo Schroeder Director | Sep 10, 2021 | Sale(10b5-1 plan) | −5,171 | $31.03 | $160.46K | 1,138,246 |
| Thilo Schroeder Director | Sep 9, 2021 | Sale(10b5-1 plan) | −14,329 | $30.31 | $434.31K | 1,181,473 |
| Leila Alland Chief Medical Officer | Sep 9, 2021 | Option exercise | +100 | $3.90 | $390 | 100 |
| Leila Alland Chief Medical Officer | Sep 9, 2021 | Sale(10b5-1 plan) | −100 | $30.25 | $3.03K | 0 |
| Leila Alland Chief Medical Officer | Sep 7, 2021 | Option exercise | +3,900 | $3.90 | $15.21K | 3,900 |
| Leila Alland Chief Medical Officer | Sep 7, 2021 | Sale(10b5-1 plan) | −3,900 | $30.25 | $117.98K | 0 |
| Thilo Schroeder Director | Sep 2, 2021 | Sale(10b5-1 plan) | −5,400 | $30.15 | $162.81K | 1,195,802 |
| Thilo Schroeder Director | Sep 1, 2021 | Sale(10b5-1 plan) | −21,986 | $30.38 | $667.93K | 1,201,202 |
| Thilo Schroeder Director | Aug 31, 2021 | Sale(10b5-1 plan) | −19,520 | $30.12 | $587.94K | 1,223,188 |
| Thilo Schroeder Director | Aug 30, 2021 | Sale(10b5-1 plan) | −13,233 | $30.05 | $397.65K | 1,242,708 |
| Thilo Schroeder Director | Aug 27, 2021 | Sale(10b5-1 plan) | −1,045 | $31.06 | $32.46K | 1,255,941 |
| Thilo Schroeder Director | Aug 27, 2021 | Sale(10b5-1 plan) | −23,397 | $30.50 | $713.61K | 1,256,986 |
| Thilo Schroeder Director | Aug 26, 2021 | Sale(10b5-1 plan) | −6,091 | $31.13 | $189.61K | 1,280,383 |
| Thilo Schroeder Director | Aug 26, 2021 | Sale(10b5-1 plan) | −15,063 | $30.39 | $457.76K | 1,286,474 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of PMV Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,474 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Private Investments V, LP Shareholder | Oct 23, 2025 | 1,000,000 | $1.52M | Oct 23, 2025 | Initial Public Offering |
| OrbiMed Private Investments V, LP Shareholder | Sep 10, 2025 | 2,283,654 | $3.65M | Sep 10, 2025 | Initial Public Offering |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Nov 22, 2023 | 87,786 | $197.52K | Nov 22, 2023 | Initial Public Offering |
See a number that looks wrong?